---
layout: post
title: "Qualified Infectious Disease Product Designation-Questions and Answers; Guidance for Industry; Availability"
date: 2026-02-05 19:09:39 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-09986
original_published: 2021-05-12 00:00:00 +0000
significance: 8.00
---

# Qualified Infectious Disease Product Designation-Questions and Answers; Guidance for Industry; Availability

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** May 12, 2021 00:00 UTC
**Document Number:** 2021-09986

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Qualified Infectious Disease Product Designation--Questions and Answers." The Food and Drug Administration Safety and Innovation Act (FDASIA) created incentives for the development of antibacterial and antifungal drug products that treat serious or life-threatening infections. The purpose of this final guidance is to provide a resource for information on FDA's policies and procedures related to the designation of a qualified infectious disease product (QIDP). This guidance finalizes the draft guidance of the same name issued on January 30, 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/05/12/2021-09986/qualified-infectious-disease-product-designation-questions-and-answers-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2021-09986

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
